

1 Seroprevalence and associated factors of maternal 2 cytomegalovirus in Southern Ethiopia

3 *Mengistu Hailemariam Zenebe^{1, 2, 3}, Zeleke Mekonnen², Eskindir Loha^{4, 5} and Elizaveta
4 Padalko^{3, 6}

5 ¹School of Medical Laboratory Sciences, Hawassa University college of Medicine and Health
6 Sciences, Hawassa, Ethiopia

7 ² School of Medical Laboratory Sciences, Jimma University Institute of Health
8 Jimma University, Jimma, Ethiopia

9 ³ Department of Diagnostic Sciences, Ghent University, Ghent, Belgium

10 ⁴ Centre for International Health, University of Bergen, Bergen, Norway

11 ⁵ Chr. Michelson Institute, Bergen, Norway

12 ⁶ Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium

13

14 *Corresponding author, mailing address: School of laboratory science Hawassa University

15 P.o.Box=1560, Hawassa, Ethiopia, Phone: (+251913641103), E-mail address:

16 mengemariamzenebe@gmail.com

17

18

19 Abstract

20 **Introduction:** Cytomegalovirus (CMV) is the most common infection during pregnancy that
21 poses the risk of congenital CMV infections (cCMV) worldwide. The aim of this study was to
22 assess the seroprevalence and associated factors of CMV among pregnant women in Southern
23 Ethiopia.

24 **Method:** A cross-sectional study was conducted on consecutive women attending the delivery
25 ward at Hawassa comprehensive and specialized hospital. Blood samples collected at the time of
26 delivery were tested for CMV IgG and IgM using ELISA. Study participants responded to a
27 questionnaire about obstetric history and socio-demographic characteristics. Data analysis was
28 performed using SPSS version 20.0 software. Chi-square, bivariable and multivariable logistic
29 regression were used to identify characteristics independently associated with the sero-status of
30 CMV.

31 **Results:** Seropositivity for CMV IgM antibodies was 8.2% (49/600) (95% CI: 6 -10.5%),
32 whereas the CMV IgG was 88.6% (532/600), (95% CI: 89.5 - 94.0%). Seroprevalence was
33 higher in women of older age, currently unmarried and having nursery schooled children.
34 Moreover CMV seropositivity was significantly associated with any of detected curable STIs.
35 Seroprevalence was not significantly related to previous adverse pregnancy outcome, gravidity,
36 being a child day care occupant mother, and birth weight of the newborn.

37 **Conclusion:** In the present study, we identified a high rate of CMV IgM seropositivity among
38 pregnant women in southern Ethiopia. Given that there is no existing CMV diagnosis, special
39 attention should be designed for pregnant women in parallel to the existing antenatal care
40 facility. Besides, training health care professionals will support awareness conception among
41 pregnant women concerning the sequels of CMV infection during pregnancy.

42 Key questions

43

44 What is already known?

45 • Cytomegalovirus is the most common infection during pregnancy that can cause
46 congenital CMV infections and known to cause long-term sequelae including
47 sensorineural hearing loss of the developing fetus.

48 • However, data on maternal CMV infection lacking in Ethiopia besides there is no
49 maternal CMV diagnostics and screening service for pregnant women.

50 What are the new findings?

51 • A high prevalence 8.3% of CMV IgM and 88.6% of CMV IgG documented.

52 • Seroprevalence associated with older age women, currently unmarried and having
53 nursery schooled children in the household. Also CMV seropositivity was significantly
54 associated with any of detected curable STIs.

55 What do the new findings imply?

56 • Known that there is no existing maternal CMV screening in Ethiopia, understanding the
57 burden and the effect of maternal CMV infection will offer important information to the
58 health care providers to prevent a sequel to the developing fetus.

59 • The current study provides valuable information on the associated factors with maternal
60 CMV infection hence, training health care professionals will support awareness
61 conception among pregnant women concerning the sequels for CMV infection during
62 pregnancy.

63 Introduction

64 Cytomegalovirus (CMV) is the most common infection during pregnancy that poses the risk of
65 congenital CMV infections (cCMV) worldwide.(1) In immunocompetent hosts, primary CMV
66 infection may be asymptomatic or may cause mild self-limiting disease with fever, headaches,
67 and myalgia and after primary infection the virus remains latent. Latency following a primary
68 infection may relapse by periodic reactivations that give rise to recurrent infections later in life
69 when the body immunity is suppressed.(2)

70 CMV infection or reactivation during pregnancy is mostly asymptomatic, however may lead to
71 fetal infection and cCMV syndromes.(3) Congenital CMV infection of the fetus of mothers
72 having pre-existing anti-CMV antibodies is also possible due to risk of reactivation or reinfection
73 with a different strain of CMV during pregnancy.(4) Therefore unlike previous perception the
74 high maternal CMV seroprevalence in developing countries like Ethiopia does not eliminate the
75 threat of cCMV infection of the newborn. Worldwide cCMV following nonprimary maternal
76 infections is more common in individuals of lower socioeconomic background.(5)

77 So far studies have shown maternal seropositivity rates of previous infection ranging from low
78 (50 to 70%) in developed countries, to high (>70%) in developing countries.(1) Presently, data
79 on the prevalence of maternal CMV and associated risk factors are scanty in Ethiopia. The only
80 available study conducted in Ethiopia had reported the prevalence of 15.5% for IgM and 88.6%
81 for CMV IgG.(6)

82 In Africa the highest prevalence of CMV IgG was estimated ranging from 72 – 97.5% (7, 8) and
83 of CMV IgM antibodies ranging from 0-15.5%.(9) However, for several reasons CMV infection

84 among pregnant women in Africa have been overlooked.(10) One of the main reasons for
85 inattention is the perception that being infected in early childhood endures immunity for
86 subsequent infection, so maternal reactivation or reinfection during pregnancy is unlikely to
87 cause severe congenital infection.(11) However, in pregnant women the immune system is
88 somehow suppressed. So ignoring maternal CMV and the subsequent effect of cCMV infection
89 in Africa is short-sighted; furthermore, the possible confounding effects of HIV infection,
90 malnutrition, tuberculosis, and a general higher disease burden of the continent must be taken
91 into account.(12)

92 The objective of the study was to assess the seroprevalence of CMV among pregnant women and
93 determine associated factors in Southern Ethiopia. Information about maternal the prevalence of
94 CMV and associated risk factors is almost absent in Ethiopia and this study was the first in the
95 southern region. We hope the study will attract health care professional attention and improve
96 antenatal care in this domain. In the meantime it will generate awareness to the community,
97 mainly pregnant women, regarding the consequence of CMV during pregnancy in Ethiopia.

98 Methodology

99 Study setting and recruitment

100 From August to October 2020, a cross-sectional study was conducted among pregnant women
101 who came for delivery in the obstetrics ward at Hawassa University Comprehensive and
102 Specialized Hospital (HU-CSH), Ethiopia. Interrelated with the first phase of this project, where
103 the initial 350 pregnant women had been tested for curable STI (*C. trachomatis*, *N. gonorrhoeae*
104 and *T. vaginalis*) using GeneXpert (Xpert CT/NG and Xpert TV assays, Cepheid, Sunnyvale,

105 California, USA), our manuscript being submitted and under review (manuscript number PONE-
106 D-20-37668). In this second phase of the study, by including those initially enrolled 350
107 pregnant women, a total of 600 consecutively enrolled pregnant women were participated.
108 Pregnant women were recruited upon delivery regardless of gestational age. A midwife at the
109 obstetric ward provided general information about the study to all pregnant women before
110 recruitment.

111 **Socio-demographic, obstetric and behavioral data**

112 Trained midwife at the obstetric ward provided general information about the study to pregnant
113 women who came for delivery. Pregnant women agreeing to join in the study were interviewed
114 using a structured questionnaire translated in Amharic, the language spoken by most people in
115 the study area. The translated questionnaire was pre-tested on random mother at antenatal clinic
116 to ensure the validity and feasibility of the questions as conducted in similar studies. Information
117 related to socio-demographic characteristics (e.g., age, marital status, and educational level),
118 obstetric history, and behavioral data were collected.

119 **Sample collection and storage**

120 The midwife-nurse aseptically collected a 3 ml blood sample from each subject. The collected
121 samples were transported to the HU-CMHS microbiology laboratory within 12 hours of
122 collection and the processed serums stored at -20 C^0 until analysis.

123 **Laboratory methods**

124 Testing was performed in Belgium, Ghent University hospital, department of laboratory
125 medicine, using a commercially available enzyme immunoassay (ELISA) kit (EUROIMMUN
126 Medizinische Labordiagnostika AG, Lübeck, Germany) for anti-CMV IgG and IgM according to
127 the manufacturer's instructions. Results were evaluated semi-quantitatively by calculating a ratio
128 of the extinction value of the patient sample over the extinction value of the calibrator optical
129 density at 450 nm. Seropositivity was defined according to the guidelines given by the
130 manufacturer, CMV negative when the ratio cut off value was < 0.8 , borderline between 0.8 and
131 1.1, and positive if > 1.1 for both IgG and IgM.

132 **Ethical considerations**

133 Ethical approval from all of the appropriate institutional review boards was obtained. The ethics
134 review committee of Hawassa University (CMHS/283/2012), Jimma University
135 (IHRPGD/458/2020), National Health Research Ethics Review Committee (SRA/14.1/
136 144483/2020) Ethiopia, and Ghent University (PA2019-038/BC-08458) Belgium, approved the
137 study. All participants provided written, informed consent for study participation.

138 **Data analysis**

139 Descriptive statistics were used to characterize the socio-demographic and obstetric and medical
140 characteristics of the participants. We evaluated the seroprevalence of CMV and associated
141 factors using a logistic regression model. Bivariate comparisons using Chi-square or Fisher's
142 exact test where suitable were used to examine the relationships between participant
143 characteristics and CMV test result. Finally, multivariable logistic regression was used to

144 identify characteristics independently associated with sero-status of CMV and adjusting for other
145 factors. Variables with a significant level of ≤ 0.2 were included in the final model. P value <
146 0.05 is considered statistically significant. SPSS software version 20.0 (SPSS Inc. Chicago, IL,
147 USA) was used for all analyses.

148 Results

149 Six hundred pregnant women were assessed for seroprevalence of CMV. The mean of maternal
150 age was $27.0 \pm$ (SD) 5.2, with a ranging between 17 and 41. More than one-third of the study
151 participant were under the age of 25. About one-fourth of the women were Primigravida. Out of
152 the 600 participant 84 (14%) were currently unmarried, 475 (79.2%) were residing in urban
153 setting, 377 (62%) were above or at secondary level of education. Forty-eight (8%) of the
154 newborns were under-weighted (<2.5 Kg), and 64 (10%) of the births were preterm. Regarding
155 STIs test result, 51 (14.6%) pregnant women were tested positive for any of curable STIs (Table
156 1).

157 In this study, around 96% of mothers had no knowledge of congenitally transmitted infection or
158 the associated risks in pregnancy and about 9% of them had previous adverse pregnancy
159 outcome. The chi-square analysis shown that, seropositivity for CMV IgM significantly
160 associated ($p < 0.05$) with marital status, gestational age, having nursery school baby in the
161 household, sharing a cup with children and having any of detected curable STIs. However, there
162 was no significant association with birth weight, gravidity and having previous adverse
163 pregnancy outcome i.e. preterm birth, stillbirths and early neonatal death (Table 1).

164 **Table 1 Maternal characteristics and associated factor with CMV IgM seropositivity in**
 165 **Southern Ethiopia**

Characteristics	Total (N=600) n (%)	IgM-Positive (n=49) n (%)	IgM-Negative (n=551) n (%)	p-value
Age of mothers (years)				
<25	233 (38.8)	14 (28.6)	219 (39.7)	0.148
25-29	162 (27.0)	14 (28.6)	148 (26.9)	
30- 35	170 (28.3)	15 (30.6)	155 (28.1)	
>35	35 (5.8)	6(12.2)	29 (5.3)	
Marital status				
Married	516 (86.0)	37 (75.5)	479 (86.9)	
Currently unmarried	84 (14.0)	12 (24.5)	72 (13.1)	0.027
Residence				
Urban	475 (79.2)	44 (89.8)	431 (78.2)	0.056
Rural	125 (20.8)	5 (10.2)	120 (21.8)	
ANC follow up during pregnancy				
Yes	576 (96.0)	48 (98.0)	528 (95.8)	
no	24 (4.0)	1 (2.0)	23 (4.2)	0.712
Employed as daycare worker				
Yes	40 (6.7)	6 (12.2)	34 (6.2)	0.126
No	560 (93.3)	43 (87.8)	517 (93.8)	
Employed as health care				
Yes	32 (5.3)	6 (12.2)	26 (4.7)	0.055
no	568 (94.7)	43 (87.8)	525 (95.3)	
Education				
Primary and below	223 (37.2)	13 (26.5)	210 (38.1)	0.108

Secondary and above	377 (62.8)	36 (73.5)	341 (61.9)	
Gestational age				
Term	536 (89.3)	36 (73.5)	500 (90.7)	
Preterm	64 (10.7)	13 (26.5)	51 (9.3)	<0.001
Birth weight				
<2.5 Kg	48 (8.0)	3 (6.1)	45 (8.2)	0.789
>2.5 Kg	552 (92.0)	46 (93.9)	506 (91.8)	
Gravidity				
Primigravida	147 (24.5)	14 (28.6)	133 (24.1)	0.489
Multigravida	453(75.5)	35 (71.4)	418 (75.9)	
Previous adverse pregnancy outcome *				
Yes	39 (8.6)	2 (5.7)	37 (8.9)	0.756
No	414 (91.4)	33 (94.3)	381 (91.1)	
Knowledge on congenitally transmitted infections				
Yes	25 (4.2)	1 (2.0)	24 (4.4)	
No	575 (95.8)	48 (98.0)	527 (95.6)	0.712
Under-five children in the household				
Yes	396 (66.0)	31 (63.3)	365 (66.2)	0.673
no	204 (43.0)	18 (36.7)	186 (33.8)	
Daycare or Nursery school baby in the household				
Yes	259 (43.2)	31 (63.3)	228 (41.4)	0.003
no	341 (56.8)	18 (36.7)	323 (58.6)	
Sharing feeding cup with children				
Yes	107 (17.8)	14 (28.6)	93 (16.9)	0.040
no	493 (82.2)	35 (71.4)	458 (83.1)	

Sharing eating utensil with children				
Yes	88 (14.7)	8 (16.3)	80 (14.5)	0.732
No	512 (85.3)	41 (83.7)	471 (85.5)	
Sharing teeth brush with children				
Yes	42 (7.0)	3 (6.1)	39 (7.1)	0.999
No	558 (93.0)	46 (93.9)	512 (92.9)	
<i>N.gonorrhoeae</i> detected (n=350)				
Yes	15 (4.3)	3 (10.0)	12 (3.8)	0.128
No	333 (95.7)	27 (90.0)	306 (96.2)	
<i>C. trachomatis</i> detected (n=350)				
Yes	29 (8.3)	5 (16.7)	24 (7.5)	0.089
No	319 (91.7)	25 (83.3)	294 (92.5)	
<i>T. vaginalis</i> detected (n=350)				
Yes	11 (3.1)	2 (6.9)	9 (2.8)	0.241
No	335 (96.8)	27 (93.1)	308 (97.2)	
Any of curable STI detected (n=350)				
Yes	51 (14.6)	10 (33.3)	41 (12.8)	0.005
No	299 (85.4)	20 (66.7)	279 (87.2)	

166

167

168 *previous adverse pregnancy includes; early neonatal death, stillbirth and preterm birth : STI; Sexually
 169 transmitted infections

170 Seroprevalence

171 Seropositivity of CMV IgM antibodies was 8.2% (49/600) (95% CI: 6 -10.5%), whereas
 172 seroprevalence of CMV IgG was 88.6% (532/600), (95% CI: 89.5 - 94.0%). Of 532 CMV IgG
 173 positive women, 483 (80.4%) were negative for IgM. Among all pregnant women, 68 (11.4%)

174 were tested negative for both anti-CMV IgG and IgM, and none showed anti-CMV IgG
175 negativity but IgM positivity (Table 2).

176 **Table 2 Cytomegalovirus IgM and IgG test result of pregnant women**

Anti CMV IgM antibody	Anti CMV IgG antibody n (%)		Total n (%)
	Positive	Negative	
Positive	49 (8.2)	0 (0)	49 (8.2)
Negative	483 (80.4)	68(11.4)	551 (91.8)
Total	532 (88.6)	68(11.4)	600

177 **CMV seropositivity and associated factors**

178 In bivariable analysis, seropositivity was more common in elder women (>35) compared to the
179 youngest age group, in women who were currently unmarried, giving preterm birth, sharing a
180 feeding cup with children or having nursery schooled children. Moreover women were positive
181 for any of curable STIs also had a higher seroprevalence of CMV compared to those negative for
182 STIs (Table 3).

183 Furthermore, in multivariable logistic regression maternal IgM seropositivity was associated
184 with elder age groups (AOR = 4.9, 95% CI: 1.0–23.4), currently unmarried women (AOR = 3.8,
185 95% CI: 1.7–7.9), preterm birth (AOR = 3.9, 95% CI: 1.5–10.3) and having nursery schooled
186 children (AOR = 2.7, 95% CI: 1.1–6.4). Mothers with STIs has an association with
187 seroprevalence (AOR = 4.1, 95% CI: 1.6–10.6) compared to mothers who were diagnosed
188 negative for STIs.

189 Maternal seroprevalence was not significantly different in relation to residence, education level,
190 to mother's occupation; being employed in child daycare or being health care worker (Table 3).

191 **Table 3. Unadjusted and adjusted associated factors of maternal CMV IgM seropositivity**
 192 **in Southern Ethiopia**

Characteristics	Un adjusted		Adjusted	
	OR 95% CI)	P-value	OR (95% CI)	P-value
Age of mothers (years)				
<25	1		1	
25-29	1.5 (0.7 -3.2)	0.318	1.2 (0.4 – 4.0)	0.739
30- 35	1.5 (0.7 -3.2)	0.283	3.0 (1.0 – 9.0)	0.048
>35	3.2 (1.2– 9.1)	0.026	4.9 (1.0 – 23.4)	0.047
Marital status				
Married	1		1	
Currently unmarried	2.2 (1.1 -4.3)	0.030	3.8 (1.3 -11.2)	0.015
Residence				
Urban	2.5 (1.0 -6.3)	0.064	2.3 (0.7 -7.9)	0.171
Rural	1		1	
Daycare worker				
Yes	2.1 (0.8 -5.3)	0.110	1.1 (0.2- 5.4)	0.857
No	1		1	
Health care worker				
Yes	2.8 (1.1 - 7.2)	0.031	1.2 (0.2 – 7.4)	0.841
no	1		1	
Education				
Primary and below	0.6 (0.3 -1.1)	0.111	0.7 (0.3 -1.8)	0.475
Secondary and above	1		1	
Gestational age				
Term	1		1	

Preterm	3.5 (1.8 – 7.1)	<0.001	3.9 (1.5 -10.3)	<0.006
Daycare or Nursery school baby				
Yes	2.4 (1.3 – 4.5)	0.004	2.7 (1.1 – 6.4)	0.027
no	1		1	
Sharing a cup with children				
Yes	2.0 (1.1 – 3.8)	0.044	2.2 (0.9 – 5.4)	0.074
no	1			
Any of curable STIs (n=350)				
Yes	3.4 (1.5- 7.8)	0.004	4.1 (1.6- 10.6)	0.003
No	1			

193

194 Discussion

195 In this study an overall 8.2% CMV IgM and 88.7% seroprevalence of CMV IgG were detected
 196 among pregnant women in southern Ethiopia. The associated factors of seropositivity were age,
 197 marital status, the presence of a curable STIs and sharing a cup with children. A statistically
 198 significant association was also observed between CMV seropositivity and preterm delivery.

199 The reported seropositivity of 88.6% CMV IgG in this study was comparable to a previous report
 200 of 88.5% h in central Ethiopia but a substantially higher rate (15.5%) of CMV IgM was detected
 201 in this study.(6) Seropositivity of CMV IgG in our study was in line with a review done in
 202 Africa, with ranges from 60% to 100%.(9) Seropositivity rates of 77.3% for IgG and 8.1% for
 203 IgM in Kenya,(7) 93% for IgG and 11.1% for IgM in Nigeria,(13) 94% for IgG and 8.5% for
 204 IgM in Tanzania(14) were comparable to our finding.

205 In our study seroprevalence of CMV IgM is in concordance with several African studies.(7, 13-
206 15) However, our rate was higher when compared to 0.4% in Tanzania,(16) 2.5% in Sudan,(17),
207 and 7% in Egypt.(18) In the absence of maternal screening this high rate is alarming for policy
208 makers. By far developed countries pregnant women are screened for CMV because of the
209 consequence for the fetus and newborn.(19, 20) However, in most developing countries
210 including Ethiopia, maternal CMV still lack awareness, overlooked and not diagnosed at least for
211 pregnant women.(21) The high rate of positive CMV IgM may not only reflect primary infection
212 but might also be attributed to reinfection or reactivation of CMV during pregnancy. So the
213 reported high seropositivity in this study point to the existing negligence and the need to start
214 screening to detect pregnant women at risk for congenital transmission of CMV.

215 In this study, elder age has significant association with seroprevalence. The same finding was
216 reported in Sudan,(17) Kenya,(22), and Tanzania.(16) In addition a large scale study in London
217 also reported that seropositivity increases with increasing age.(23) But, in a study in Egypt(18)
218 and in Nigeria(24) age had no association with maternal CMV infection. The highest
219 seroprevalence with age may indicate the more exposure of elders than youngsters or might be
220 the existence of previous infection which can probably reactivated in the current pregnancy.

221 On the other hand, significant association of seroprevalence with having nursery schooled
222 children among household was observed. For pregnant women the predictable source of CMV
223 infection is young children mainly exposure to nursery schooled children.(25) Children easily get
224 infected in school and frequently shed CMV in their saliva or urine for many years continuously
225 where spreads readily in preschool setting.(26) This places seronegative pregnant women who
226 have a young child in the home or in day care at increased risk of seroconversion.(27,
227 28) Susceptibility to acquisition of CMV infection is high possibly through the direct contact

228 with contagious secretions from their own children essentially in situation of poor hygienic
229 practice like in Ethiopia.(23)

230 Among candidate predictors for maternal CMV seropositivity, occupation like being health care
231 worker, or child day care worker; being multigravida, lower educational level and having other
232 children at home were not detected. However, significant association with women who delivered
233 preterm was reported. Although, preterm delivery might be due to the effect of maternal CMV
234 infection we can not to say the risk factor as there are a lot of other confounding factors for
235 preterm.(29)

236 Likewise, seropositivity was found to be significantly associated with STIs detected at delivery
237 and currently being unmarried. Mothers who were positive for any of curable STIs had a four-
238 time CMV seropositivity. It is also reported that STIs including CMV is more common in
239 unmarried pregnant women.(23, 25, 30) Although cytomegalovirus is a virus that is transmitted
240 through many body fluids, sexual transmission from a seropositive male partner is an additional
241 established route by which women may be infected with CMV.(31) Indeed, it is somehow
242 expected that sexual transmission is also responsible for reinfection of seropositive mothers with
243 different virus strains in high-seroprevalence populations.(32)

244 The limitations of the present study are that we lack differentiation of CMV IgM positives of
245 either primary or secondary (reinfection or reactivation) since we collected samples at the end of
246 pregnancy and avidity test will not suitable. Moreover, it was a hospital-based study and not
247 representative of all pregnant mothers in the locality since a significant portion of mothers may
248 not deliver in the hospital. We lack also appropriate risk factors assessment tool as we mainly

249 focused on seroprevalence and nature of the enrolled participant (time of labour), hence more
250 representative large scale survey is needed to identify possible risk factors prospectively.

251

252 Conclusion

253 In the present study, we documented a high rate of CMV seroprevalence among pregnant women
254 in southern Ethiopia. The presence of curable STIs, elder age, unmarried women, and having
255 nursery schooled children have a significant association with seropositivity. Given that there is
256 no existing CMV diagnostic facility, special attention should be designed for pregnant women in
257 parallel to the existing antenatal care service. Besides, training health care professionals will
258 support awareness conception for pregnant women concerning the sequels of CMV infection
259 during pregnancy.

260 Acknowledgments

261 We thank the HU-CSH microbiology laboratory staffs for provision of all laboratory
262 accommodations during sample processing and storage. We would like to recognise the study
263 participants and a special thanks to midwife nurses at the obstetrics ward of the HU-CSH. Lastly,
264 we want to express our thanks to VLIR-UOS for financial support.

265 **Author Contributions:** MH and EP contributed to the study design and conceptualisation. MH
266 carried out the laboratory work. MH, EL, ZM and EP performed the statistical analysis and
267 interpretation. All authors provided critical review and contributed to the write-up and approved
268 the final version of the manuscript. MH had final responsibility to submit for publication. All
269 authors read and amended drafts of the paper and approved the final version.

270 **Funding:** No funding was obtained. But A PhD Scholarship supported by the research from the
271 Belgian Development Cooperation through the VLIR-UOS network program (University
272 collaboration for better health in Ethiopia (UCBHE).

273 Competing interests: no competing interest

274 **Patient consent:** Obtained. All participants provided written, informed consent for study
275 participation.

276 **Ethics approval:** Ethical approval from all of the appropriate institutional review boards was
277 obtained. The ethics review committee of Hawassa University (CMHS/283/2012), Jimma
278 University (IHRPGD/458/2020), National Health Research Ethics Review Committee
279 (SRA/14.1/ 144483/2020) Ethiopia, and Ghent University (PA2019-038/BC-08458) Belgium,
280 approved the study.

281 **Data sharing statement:** No additional data are available.

282 References

- 283 1. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “Silent” Global
284 Burden of Congenital Cytomegalovirus. *Clinical microbiology reviews*. 2013;**26**(1):86-102.
- 285 2. Nolan N, Halai UA, Regunath H, Smith L, Rojas-Moreno C, Salzer W. Primary
286 cytomegalovirus infection in immunocompetent adults in the United States - A case series.
287 *IDCases*. 2017;**10**:123-6.
- 288 3. Lazzarotto T, Blázquez-Gamero D, Delforge M-L, Foulon I, Luck S, Modrow S, et al.
289 Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and
290 Management From a Panel of European Experts. *Frontiers in pediatrics*. 2020;**8**(13).
- 291 4. Britt WJ. Maternal Immunity and the Natural History of Congenital Human
292 Cytomegalovirus Infection. *Viruses*. 2018;**10**(8):405.
- 293 5. Mussi-Pinhata MM, Yamamoto AY. Natural History of Congenital Cytomegalovirus
294 Infection in Highly Seropositive Populations. *The Journal of infectious diseases*.
295 2020;**221**(Supplement_1):S15-s22.
- 296 6. Mamuye Y BN, Delayehu B, Mekonen G Seroepidemiology study of CMV and Rubella
297 among pregnant women at St. Paul’s Hospital Millennium Medical College, Addis Ababa,
298 Ethiopia . *Ethiop J Health Sciences*. 2016;**26**:427.

- 299 7. Maingi Z, Nyamache AK. Seroprevalence of Cytomegalo Virus (CMV) among pregnant
300 women in Thika, Kenya. *BMC research notes*. 2014;**7**:794-.
- 301 8. Khairi S, Intisar K, Enan K, Ishag M, Baraa A, Ali Y. Seroprevalence of cytomegalovirus
302 infection among pregnant women at Omdurman Maternity Hospital, Sudan. *Journal of Medical*
303 *Laboratory and Diagnosis*. 2013;**4**(4):45-9.
- 304 9. Mhandire D, Rowland-Jones S, Mhandire K, Kaba M, Dandara C. Epidemiology of
305 Cytomegalovirus among pregnant women in Africa. *Journal of infection in developing countries*.
306 2019;**13**(10):865-76.
- 307 10. Bates M, Brantsaeter AB. Human cytomegalovirus (CMV) in Africa: a neglected but
308 important pathogen. *Journal of virus eradication*. 2016;**2**(3):136-42.
- 309 11. Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, et al. Hearing loss in
310 children with congenital cytomegalovirus infection born to mothers with preexisting immunity.
311 *The Journal of pediatrics*. 2006;**148**(3):332-6.
- 312 12. Bates M, Brantsaeter AB. Human cytomegalovirus (CMV) in Africa: a neglected but
313 important pathogen. *Journal of virus eradication*. 2016;**2**(3):136-42.
- 314 13. Fowotade A, Okonko IO, Agbede OO, Suleiman ST. High seropositivity of IgG and IgM
315 antibodies against cytomegalovirus (CMV) among HIV-1 seropositive patients in Ilorin, Nigeria.
316 *African health sciences*. 2015;**15**(1):1-9.
- 317 14. Ray K, Mahajan M. Seroprevalence of cytomegalovirus antibodies in patients attending
318 STD and antenatal clinics. *J Commun Dis*. 1997;**29**(2):85-90.
- 319 15. Mhandire D, Duri K, Kaba M, Mhandire K, Musarurwa C, Chimusa E, et al.
320 Seroprevalence of Cytomegalovirus Infection Among HIV-Infected and HIV-Uninfected
321 Pregnant Women Attending Antenatal Clinic in Harare, Zimbabwe. *Viral immunology*.
322 2019;**32**(7):289-95.
- 323 16. Chibwe E, Mirambo MM, Kihunrwa A, Mshana SE. Magnitude of the Cytomegalovirus
324 infection among pregnant women attending antenatal clinics in the city of Mwanza, Tanzania.
325 *BMC research notes*. 2017;**10**(1):489.
- 326 17. Hamdan HZ, Abdelbagi IE, Nasser NM, Adam I. Seroprevalence of cytomegalovirus and
327 rubella among pregnant women in western Sudan. *Virology journal*. 2011;**8**:217.
- 328 18. Kamel N, Metwally L, Gomaa N, Sayed Ahmed WA, Lotfi M, Younis S. Primary
329 cytomegalovirus infection in pregnant Egyptian women confirmed by cytomegalovirus IgG
330 avidity testing. *Medical principles and practice : international journal of the Kuwait University,*
331 *Health Science Centre*. 2014;**23**(1):29-33.
- 332 19. Gyselaers W, Jonckheer P, Ahmadzai N, Ansari M, Carville S, Dworzynski K, et al.
333 What are the recommended clinical assessment and screening tests during pregnancy? Good
334 Clinical Practice (GCP) Brussels: Belgian Health Care Knowledge Centre (KCE). 2015. KCE
335 Reports 248. *KCE Reports*. 2017;248.
- 336 20. Vaudry W, Rosychuk RJ, Lee BE, Cheung PY, Pang X, Preiksaitis JK. Congenital
337 cytomegalovirus infection in high-risk Canadian infants: Report of a pilot screening study. *The*
338 *Canadian journal of infectious diseases & medical microbiology = Journal canadien des*
339 *maladies infectieuses et de la microbiologie medicale*. 2010;**21**(1):e12-9.
- 340 21. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection
341 in the mother, fetus, and newborn infant. *Clinical microbiology reviews*. 2002;**15**(4):680-715.
- 342 22. Maingi Z, Nyamache AK. Seroprevalence of Cytomegalo Virus (CMV) among pregnant
343 women in Thika, Kenya. *BMC research notes*. 2014;**7**:794.

- 344 23. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women:
345 the influence of parity. *Archives of disease in childhood*. 1992;**67**(7 Spec No):779-83.
- 346 24. Yeroh M, Aminu M, Musa B. Seroprevalence of cytomegalovirus infection amongst
347 pregnant women in Kaduna state, Nigeria. *African Journal of Clinical and Experimental*
348 *Microbiology*. 2015;**16**(1):37-44.
- 349 25. Fowler KB, Pass RF. Risk Factors for Congenital Cytomegalovirus Infection in the
350 Offspring of Young Women: Exposure to Young Children and Recent Onset of Sexual Activity.
351 *Pediatrics*. 2006;**118**(2):e286-e92.
- 352 26. Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids
353 and relevance to congenital cytomegalovirus infection. *Rev Med Virol*. 2011;**21**(4):240-55.
- 354 27. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection
355 among parents of children attending day-care centers. *The New England journal of medicine*.
356 1986;**314**(22):1414-8.
- 357 28. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk
358 factors: implications for congenital CMV. *Rev Med Virol*. 2010;**20**(5):311-26.
- 359 29. Pitlick MM, Orr K, Momany AM, McDonald EL, Murray JC, Ryckman KK.
360 Determining the prevalence of cytomegalovirus infection in a cohort of preterm infants. *Journal*
361 *of neonatal-perinatal medicine*. 2015;**8**(2):137-41.
- 362 30. Shakya S, Thingulstad S, Syversen U, Nordbø SA, Madhup S, Vaidya K, et al.
363 Prevalence of Sexually Transmitted Infections among Married Women in Rural Nepal. *Infectious*
364 *Diseases in Obstetrics and Gynecology*. 2018;2018:4980396.
- 365 31. Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE, Jr., Cannon MJ. Influence
366 of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. *Sexually*
367 *transmitted diseases*. 2008;**35**(5):472-9.
- 368 32. Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, et al. Combined
369 evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV
370 transmission. *PloS one*. 2018;**13**(1):e0189851.

371

372

373